Registro:

Referencias:

• (2017) Global Tuberculosis Report 2017, , http://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf, Available from
• Peña, D.A., Rovetta, A.I., Hernández Del Pino, R.E., Amiano, N.O., Pasquinelli, V., Pellegrini, J.M., Mycobacterium tuberculosis dormancy antigen differentiates latently infected Bacillus Calmette-Guerin vaccinated individuals (2015) EBioMedicine, 2 (8), pp. 882-888
• WHO Global Tuberculosis Programme (1994) TB: A Global Emergency, WHO Report on the TB Epidemic, , http://www.who.int/iris/handle/10665/58749, Geneva: World Health Organization, Available from
• Porcel, J.M., Leung, C.C., Restrepo, M.I., Lee, P., Year in review 2011: respiratory infections, tuberculosis, pleural diseases, bronchoscopic intervention and imaging (2012) Respirology, 17 (3), pp. 573-582
• Treatment of Tuberculosis (2017) Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care, , http://apps.who.int/iris/bitstream/handle/10665/255052/9789241550000-eng.pdf?sequence=1, Update; 2017. Available from
• Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis (2003) Am J Respir Crit Care Med, 167 (4), pp. 603-662
• Stewart, G.R.B., Young, D., Tuberculosis: a problem with persistence (2003) Nat Rev Microbiol, 1 (2), pp. 97-105
• Toossi, Z., Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease (2003) J Infect Dis, 188 (8), pp. 1146-1155
• Kaufmann, S.H., How can immunology contribute to the control of tuberculosis? (2001) Nat Rev Immunol, 1 (1), pp. 20-30
• Riley, R.M.W., Nyka, N., Weintock, P., Storey, I., Sultan, M., Wells, W., Aerial dissemination of pulmonary tuberculosis: a two year study of contagion in a tuberculosis ward (1959) Am J Hyg, 142 (1), pp. 185-196
• Fenton, M.J., Vermeulen, M.W., Immunopathology of tuberculosis: roles of macrophages and monocytes (1996) Infect Immun, 64 (3), pp. 683-690
• Stenger, S., Rollinghoff, M., Role of cytokines in the innate immune response to intracellular pathogens (2001) Ann Rheum Dis, 60 (3), pp. 43-46
• Ramakrishnan, L., Revisiting the role of the granuloma in tuberculosis (2012) Nat Rev Immunol, 12 (5), pp. 352-366
• Hashemian, S.M., Tabarsi, P., Karam, M.B., Kahkouee, S., Marjani, M., Jamaati, H., Radiologic manifestations of pulmonary tuberculosis in patients of intensive care units (2015) Int J Mycobacteriol, 4 (3), pp. 233-238
• Schnappinger, D., Ehrt, S., Voskuil, M.I., Liu, Y., Mangan, J.A., Monahan, I.M., Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment (2003) J Exp Med, 198 (5), pp. 693-704
• Flynn, J.L., Immunology of tuberculosis and implications in vaccine development (2004) Tuberculosis (Edinb), 84 (1-2), pp. 93-101
• Tateosian, N.L., Pellegrini, J.M., Amiano, N.O., Rolandelli, A., Casco, N., Palmero, D.J., IL17A augments autophagy in Mycobacterium tuberculosis-infected monocytes from patients with active tuberculosis in association with the severity of the disease (2017) Autophagy, 13 (7), pp. 1191-1204
• Ivanyi, J., Function and potentials of M. tuberculosis epitopes (2014) Front Immunol, 5, p. 107
• Abbas, A.K., Lichtman, A.H., Pillai, S., (2008) Cellular and Molecular Immunology, , Madrid: Elsevier-Saunders Inc. 6th edition
• Garcia-Prats, A.J., Willemse, M., Seifart, H.I., Jordaan, A.M., Werely, C.J., Donald, P.R., Acquired drug resistance during inadequate therapy in a young child with tuberculosis (2014) Pediatr Infect Dis J, 33 (8), pp. 883-885
• Panchagnula, R., Agrawal, S., Ashokraj, Y., Varma, M., Sateesh, K., Bhardwaj, V., Fixed dose combinations for tuberculosis: lessons learned from clinical, formulation and regulatory perspective (2004) Methods Find Exp Clin Pharmacol, 26 (9), pp. 703-772
• Preziosi, P., Isoniazid: metabolic aspects and toxicological correlates (2007) Curr Drug Metab, 8 (8), pp. 839-851
• Rivers, E.C., Mancera, R.L., New anti-tuberculosis drugs in clinical trials with novel mechanisms of action (2008) Drug Discov Today, 13 (23-24), pp. 1090-1098
• Moretton, M.A., Glisoni, R.J., Chiappetta, D.A., Sosnik, A., Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles (2010) Colloids Surf. B: Biointerfaces, 79 (2), pp. 467-479
• Gohel, M.C., Sarvaiya, K.G., A novel solid dosage form of rifampicin and isoniazid with improved functionality (2007) AAPS PharmSciTech, 8 (3)
• El-Ridy, M.S., Mostafa, D.M., Shehab, A., Nasr, E.A., Abd El-Alim, S., Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis (2007) Int J Pharm, 330 (1-2), pp. 82-88
• (2018) Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management, , http://apps.who.int/iris/bitstream/handle/10665/260233/9789241550239-eng.pdf?sequence=1, Available from
• Du Toit, L.C., Pillay, V., Danckwerts, M.P., Tuberculosis chemotherapy: current drug delivery approaches (2006) Respir Res, 7, p. 118
• (2003) Treatment of Tuberculosis. Guidelines for National Programmes, , http://apps.who.int/iris/bitstream/handle/10665/67890/WHO_CDS_TB_2003.313_eng.pdf?sequence=1, Geneva, World Health Organization, Available from
• Chang, K.-C., Yew, W.-W., Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012 (2013) Respirology, 18 (1), pp. 8-21
• Pai, M., Behr, M.A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C.C., Tuberculosis (2016) Nat Rev Dis Primers, 2
• (2016) Treatment Guidelines for Drug-Resistant Tuberculosis, , http://apps.who.int/iris/bitstream/handle/10665/250125/9789241549639-eng.pdf;jsessionid=8E57A036E76B0B028129B6AC6678C423?sequence=1, update. Available from
• Caminero, J.A., Scardigli, A., Classification of antituberculosis drugs: a new proposal based on the most recent evidence (2015) Eur Respir J, 46 (4), pp. 887-893
• Falzon, D., Jaramillo, E., Schünemann, H.J., Arentz, M., Bauer, M., Bayona, J., WHO guidelines for the programmatic management of drug resistant tuberculosis: 2011 update (2011) Eur Respir J, 38 (3), pp. 516-528
• Tiberi, S., Scardigli, A., Centis, R., D'Ambrosio, L., Muñoz-Torrico, M., Salazar-Lezama, M.Á., Classifying new anti-TB drugs: rationale and future perspectives (2017) Int J Infect Dis, 56, pp. 181-184
• The use of delamanid in the treatment of multidrug-resistant tuberculosis (2014) Interim Policy Guidance. WHO/HTM/TB2014.23, , http://apps.who.int/iris/bitstream/handle/10665/137334/WHO_HTM_TB_2014.23_eng.pdf?sequence=1, Geneva: World Health Organization, Available from
• Harausz, E.P., Garcia-Prats, A.J., Seddon, J.A., Schaaf, H.S., Hesseling, A.C., Achar, J., On behalf of the sentinel project on pediatric drug-resistant tuberculosis. New drugs, repurposed drugs, and novel regimens for children with multidrug-resistant tuberculosis: practice-based recommendations (2016) Am J Respir Crit Care Med, 195 (10), pp. 1-58
• Gler, M.T., Skripconoka, V., Sanchez-Garavito, E., Xiao, H., Cabrera-Rivero, J.L., Vargas-Vasquez, D.E., Delamanid for multidrug-resistant pulmonary tuberculosis (2012) N Engl J Med, 366 (23), pp. 2151-2160
• Tadolini, M., Lingtsang, R.D., Tiberi, S., Enwerem, M., D'Ambrosio, L., Sadutshang, T.D., First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline (2016) Eur Respir J, 48 (3), pp. 935-938
• Wallis, R.S., Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine (2016) Eur Respir J, 48 (5), pp. 1526-1527
• Laghari, M., Darwis, Y., Memon, A.H., Khan, A.A., Abdulbaqi, I.M.T., Assi, R.A., Nanoformulations and clinical trial candidates as probably effective and safe therapy for tuberculosis (2016) Trop J Pharm Res, 15 (1), pp. 201-211
• Bawarski, W.E., Chidlowsky, E., Bharali, D.J., Mousa, S.A., Emerging nanopharmaceuticals (2008) Nanomedicine, 4 (4), pp. 273-282
• Abed, N., Couvreur, P., Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections (2014) Int J Antimicrob Agents, 43 (6), pp. 485-496
• Changsan, N., Chan, H.K., Separovic, F., Srichana, T., Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation (2009) J Pharm Sci, 98 (2), pp. 628-639
• Manca, M.L., Sinico, C., Maccioni, A.M., Diez, O., Fadda, A.M., Manconi, M., Composition influence on pulmonary delivery of rifampicin liposomes (2012) Pharmaceutics, 4 (4), pp. 590-606
• Chimote, G., Banerjee, R., In vitro evaluation of inhalable isoniazid-loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis (2010) J Biomed Mater Res B Appl Biomater, 94 (1), pp. 1-10
• Booysen, L.L., Kalombo, L., Brooks, E., Hansen, R., Gilliland, J., Gruppo, V., In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid (2013) Int J Pharm, 444 (1-2), pp. 10-17
• Merisko-Liversidge, E., Liversidge, G.G., Cooper, E.R., Nanosizing: a formulation approach for poorly-water-soluble compounds (2003) Eur J Pharm Sci, 18 (2), pp. 113-120
• Pooja, D., Tunki, L., Kulhari, H., Reddy, B.B., Sistla, R., Characterization, biorecognitive activity and stability of WGA grafted lipid nanostructures for the controlled delivery of rifampicin (2015) Chem Phys Lipids, 193, pp. 11-17
• Singh, H., Bhandari, R., Kaur, I.P., Encapsulation of rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with isoniazid at acidic pH (2013) Int J Pharm, 446 (1-2), pp. 106-111
• Singh, H., Jindal, S., Singh, Sharma G, Kaur IP. Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety (2015) Int J Pharm, 485 (1-2), pp. 138-151
• Vieira, A.C.C., Chaves, L.L., Pinheiro, S., Pinto, S., Pinheiro, M., Lima, S.C., Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis (2018) Int J Pharm, 536 (1), pp. 478-485
• Banik, N., Hussain, A., Ramteke, A., Sharma, H.K., Maji, T.K., Preparation and evaluation of the effect of particle size on the properties of chitosan-montmorillonite nanoparticles loaded with isoniazid (2012) RSC Adv, 2, pp. 10519-10528
• Trousil, J., Filippov, S.K., Hrubý, M., Mazel, T., Syrová, Z., Cmarko, D., System with embedded drug release and nanoparticle degradation sensor showing efficient rifampicin delivery into macrophages (2017) Nanomedicine, 13 (1), pp. 307-315
• Gajendiran, M., Gopi, V., Elangovan, V., Murali, R.V., Balasubramanian, S., Isoniazid loaded core shell nanoparticles derived from PLGA-PEG-PLGA tri-block copolymers: in vitro and in vivo drug release (2013) Colloids Surf B: Biointerfaces, 104, pp. 107-115
• Pandey, R., Khuller, G.K., Nanoparticle-based oral drug delivery system for an injectable antibiotic - streptomycin. Evaluation in a murine tuberculosis model (2007) Chemotherapy, 53 (6), pp. 437-441
• Pandey, R., Sharma, A., Zahoor, A., Sharma, S., Khuller, G.K., Prasad, B., Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis (2003) J Antimicrob Chemother, 52 (6), pp. 981-986
• Ahmad, Z., Sharma, S., Khuller, G.K., Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis (2005) Int J Antimicrob Agents, 26 (4), pp. 298-303
• Cagel, M., Tesan, F.C., Bernabeu, E., Salgueiro, M.J., Zubillaga, M.B., Moretton, M.A., Polymeric mixed micelles as nanomedicines: achievements and perspectives (2017) Eur J Pharm Biopharm, 113, pp. 211-228
• Owen, S.C., Chan, D.P.Y., Shoichet, M.S., Polymeric micelle stability (2012) Nano Today, 7, pp. 53-65
• Moretton, M.A., Höcht, C., Taira, C., Sosnik, A., Rifampicin-loaded ‘flower-like’ polymeric micelles for enhanced oral bioavailability in an extemporaneous liquid fixed-dose combination with isoniazid (2014) Nanomedicine (London), 9 (11), pp. 1635-1650
• Moretton, M.A., Chiappetta, D.A., Sosnik, A., Cryoprotection-lyophilization and physical stabilization of rifampicin-loaded flower-like polymeric micelles (2012) J R Soc Interface, 9 (68), pp. 487-502
• Grotz, E., Bernabeu, E., Pappalardo, M., Chiappetta, D.A., Moretton, M.A., Nanoscale Kolliphor® HS 15 micelles to minimize rifampicin selfaggregation in aqueous media (2017) J Drug Deliv Sci Technol, 41, pp. 1-6
• Praphakar, R.A., Munusamy, M.A., Rajan, M., Development of extended-voyaging anti-oxidant linked amphiphilic polymeric Nanomicelles for anti-tuberculosis drug delivery (2017) Int J Pharm, 524 (1-2), pp. 168-177
• Upadhyay, S., Khan, I., Gothwal, A., Pachouri, P.K., Bhaskar, N., Gupta, U.D., Conjugated and entrapped HPMA-PLA Nano-polymeric micelles based dual delivery of first line anti TB drugs: improved and safe drug delivery against sensitive and resistant Mycobacterium tuberculosis (2017) Pharm Res, 34 (9), pp. 1944-1955
• Jain, J.P., Ayen, W.Y., Kumar, N., Self assembling polymers as Polymersomes for drug delivery (2011) Curr Pharm Des, 17 (1), pp. 65-79
• Chang, H.-Y., Sheng, Y.-J., Tsao, H.-K., Structural and mechanical characteristics of Polymersomes (2014) Soft Matter, 10 (34), pp. 6373-6681
• Moretton, M.A., Cagel, M., Bernabeu, E., Gonzalez, L., Chiappetta, D.A., Nanopolymersomes as potential carriers for rifampicin pulmonary delivery (2015) Colloids Surf B: Biointerfaces, 136, pp. 1017-1025
• Moghassemi, S., Hadjizadeh, A., Nano-niosomes as nanoscale drug delivery systems: an illustrated review (2014) J Control Release, 185 (1), pp. 22-36
• Junyaprasert, V.P., Teeranachaideekul, V., Supaperm, T., Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes (2008) AAPS PharmSciTech, 9 (3), pp. 851-859
• El-Ridy, M.S., Abdelbary, A., Nasr, E.A., Khalil, R.M., Mostafa, D.M., El-Batal, A.I., Niosomal encapsulation of the antitubercular drug, pyrazinamide (2011) Drug Dev Ind Pharm, 37 (9), pp. 1110-1118
• El-Ridy, M.S., Yehia, S.A., Kassem, M.A., Mostafa, D.M., Nasr, E.A., Asfour, M.H., Niosomal encapsulation of ethambutol hydrochloride for increasing its efficacy and safety (2015) Drug Delivery, 22 (1), pp. 21-36
• Mehta, S.K., Jindal, N., Kaur, G., Quantitative investigation, stability and in vitro release studies of anti-TB drugs in triton niosomes (2011) Colloids Surf B: Biointerfaces, 87 (1), pp. 173-179
• Mehta, S.K., Jindal, N., Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs (2013) Colloids Surf B: Biointerfaces, 101, pp. 434-441
• (2016) Frequently Asked Questions about the Implementation of the New WHO Recommendation on the Use of the Shorter MDR-TB Regimen under Programmatic Conditions, , http://www.who.int/tb/areas-of-work/drug-resistanttb/treatment/FAQshorter_MDR_regimen.pdf, Available from
• Adikwu, E., Deo, O., Fluoroquinolones reported hepatotoxicity (2012) Pharmacology and Pharmacy, 3, pp. 328-336
• Mustafa, S., Devi, V.K., Pai, R.S., Effect of PEG and water-soluble chitosan coating on moxifloxacin-loaded PLGA long-circulating nanoparticles (2016) Drug Deliv Transl Res, 7 (1), pp. 27-36
• Sarfraz, M., Shi, W., Gao, Y., Clas, S.D., Roa, W., Bou-Chacra, N., Immune response to antituberculosis drug-loaded gelatin and polyisobutyl-cyanoacrylate nanoparticles in macrophages (2016) Ther Deliv, 7 (4), pp. 213-228
• Bhardwaj, A., Mehta, S., Yadav, S., Singh, S.K., Grobler, A., Goyal, A.K., Pulmonary delivery of antitubercular drugs using spray-dried lipid – polymer hybrid nanoparticles (2015) Artif Cells Nanomed Biotechnol, 44 (6), pp. 1544-1555
• Adams, L.B., Sinha, I., Franzblau, S.G., Krahenbuhl, J.L., Mehta, R.T., Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated Clofazimine (1999) Antimicrob Agents Chemother, 43 (7), pp. 1638-1643
• Gaidukevich, S.K., Mikulovich, Y.L., Smirnova, T.G., Andreevskaya, S.N., Sorokoumova, G.M., Chernousova, L.N., Antibacterial effects of liposomes containing phospholipid Cardiolipin and fluoroquinolone Levofl oxacin on Mycobacterium tuberculosis with extensive drug resistance (2016) Bull Exp Biol Med, 160 (5), pp. 675-676
• Breen, R.A., Swaden, L., Ballinger, J., Lipman, M.C., Tuberculosis and HIV co-infection: a practical therapeutic approach (2006) Drugs, 66 (18), pp. 2299-2308
• (2018) Managing Drug Interactions in the Treatment of Hiv-Related Tuberculosis, , https://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/recommendations03.htm, Available from
• Gaspar, M.M., Cruz, A., Penha, A.F., Reymăo, J., Sousa, A.C., Eleutério, C.V., Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis (2008) Int J Antimicrob Agents, 31 (1), pp. 37-45
• (2015) The End TB Strategy, , http://www.who.int/tb/End_TB_brochure.pdf?ua=1, Available from
• (2018) Interim Guidance on the Use of Bedaquiline to Treat MDR-TB, , http://www.who.int/tb/challenges/mdr/bedaquiline/en/, Available from
• Field, S.K., Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment? (2015) Ther Adv Chronic Dis, 6 (4), pp. 170-184
• (2015), https://www.clinicaltrials.gov/ct2/show/NCT02454205?term=bedaquiline&rank=28, Identifier NCT02454205. Available from; (2015) The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB (STREAM), , https://www.clinicaltrials.gov/ct2/show/NCT02409290?term=stream&rank=8, Identifier NCT02409290, Available from
• (2017) Safety and Efficacy of Various Doses and Treatment Durations of Linezolid plus Bedaquiline and Pretomanid in Participants with Pulmonary TB, XDR-TB, Pre- XDR-TB Or Non-Responsive/Intolerant MDR-TB (Zenix), , https://www.clinicaltrials.gov/ct2/show/NCT03086486?term=bedaquiline&rank=15, Identifier NCT03086486, Available from
• (2014), https://www.clinicaltrials.gov/ct2/show/NCT02193776?term=bedaquiline&rank=14, A Phase 2 Open Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. (NC-005), Identifier NCT02193776. Available from; (2013) The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis, , http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf, Available from
• Ritsema, J.A.S., Herschberg, E.M.A., Borgos, S.E., Løvmo, C., Schmid, R.Y.M., Te Welscher, Y.M., Relationship between polarities of antibiotic and polymer matrix on nanoparticle formulations based on aliphatic polyesters Int J Pharm 2017, , https://doi.org/10.1016/j.ijpharm.2017.11.017, Article in press
• De Matteis, L., Jary, D., Lucía, A., García-Embid, S., Serrano-Sevilla, I., Pérez, D., New active formulations against M. tuberculosis: Bedaquiline encapsulation in lipid nanoparticles and chitosan nanocapsules (2018) Chem Eng J, 340, pp. 181-191
• Bertrand, N., Wu, J., Xu, X., Kamaly, N., Farokhzad, O.C., Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology (2014) Adv Drug Deliv Rev, 66, pp. 2-25
• Traini, D., Young, P.M., Drug delivery for tuberculosis: is inhaled therapy the key to success? (2017) Ther Deliv, 8 (10), pp. 819-821
• Irache, J.M., Salman, H.H., Gamazo, G., Espuelas, S., Mannose-targeted systems for the delivery of therapeutics (2008) Expert Opin Drug Deliv, 5 (6), pp. 703-724
• Song, X., Lin, Q., Guo, L., Fu, Y., Han, J., Ke, H., Rifampicin loaded Mannosylated cationic nanostructured lipid carriers for alveolar macrophage-specific delivery (2015) Pharm Res, 32 (5), pp. 1741-1751
• Vieira, A.C.C., Chaves, L.L., Pinheiro, M., Costa Lima, S.A., Ferreira, D., Bruno Sarmento, B., Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages (2018) Artif Cells Nanomed Biotechnol, 12, pp. 1-11
• Maretti, E., Costantino, L., Rustichelli, C., Leo, E., Croce, M.A., Buttini, F., Surface engineering of solid lipid nanoparticle assemblies by methyl α-D-mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy (2017) Int J Pharm, 528 (1-2), pp. 440-451
• Costa, A., Sarmento, B., Seabra, V., Mannose-functionalized solid lipid nanoparticles are effective in targeting alveolar macrophages (2018) Eur J Pharm Sci, 114, pp. 103-113
• Moretton, M.A., Chiappetta, D.A., Andrade, F., das Neves J, Ferreira D, Sarmento B, et al. hydrolyzed galactomannan-modified nanoparticles and flower-like polymeric micelles for the active targeting of rifampicin to macrophages (2013) J Biomed Nanotechnol, 9 (6), pp. 1076-1087
• Madaan, K., Kumar, S., Poonia, N., Lather, V., Pandita, D., Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues (2014) J Pharm Bioallied Sci, 6 (3), pp. 139-150
• Kumar, P.V., Asthana, A., Dutta, T., Jain, N.K., Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers (2006) J Drug Target, 14 (8), pp. 546-556
• Katoh, S., Miyagi, T., Taniguchi, H., Matsubara, Y.-I., Kadota, J.-I., Tominaga, A., Cutting edge: an inducible Sialidase regulates the hyaluronic acid binding ability of CD44-bearing human monocytes (1999) J Immunol, 162 (9), pp. 5058-5061
• Gao, Y., Sarfraz, M.K., Clas, S.D., Roa, W., Löbenberg, R., Hyaluronic acid-tocopherol succinate-based self-assembling micelles for targeted delivery of rifampicin to alveolar macrophages (2015) J Biomed Nanotechnol, 11 (8), pp. 1312-1329
• (2015) Global TB Report, , http://www.who.int/iris/handle/10665/191102, Available from, Accessed Sept 2018
• Zwerling, A., Dowdy, D., von Delft, A., Taylor, H., Merritt, M.W., Incorporating social justice and stigma in cost-effectiveness analysis: drug-resistant tuberculosis treatment (2017) Int J Tuberc Lung Dis, 21 (11), pp. 69-74
• Moghimi, S.M., Hunter, A.C., Murray, J.C., Nanomedicine: current status and future prospects (2005) FASEB J, 19 (3), pp. 311-330
• Patil, K., Bagade, S., Bonde, S., Sharma, S., GauravSaraogi, G., Recent therapeutic approaches for the management of tuberculosis: challenges and opportunities (2018) Biomed Pharmacother, 99, pp. 735-745
• Mohammad, I.S., He, W., Yin, L., Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR (2018) Biomed Pharmacother, 100, pp. 335-348
• te Brake, L.H.M., de Knegt, G.J., de Steenwinkel, J.E., van Dam, T.J.P., Burger, D.M., Russel, F.G.M., The role of efflux pumps in tuberculosis treatment and their promise as a target in drug development: unraveling the black box (2018) Annu Rev Pharmacol Toxicol, 58, pp. 271-291
• Li, P., Gu, Y., Li, J., Xie, L., Li, X., Xie, J., Mycobacterium tuberculosis major facilitator superfamily transporters (2017) J Membr Biol, 250 (6), pp. 573-585
• Hamed, K., Debonnett, L., Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence (2017) Ther Adv Respir Dis, 11 (5), pp. 193-209
• Manconi, M., Manca, M.L., Valentia, D., Escribano, E., Hillaireau, H., Anna Maria Fadda, A.M., Chitosan and hyaluronan coated liposomes for pulmonary administration of curcumin (2017) Int J Pharm, 525 (1), pp. 203-210
• Wang, L., Zhou, Y., Wu, M., Wu, M., Li, X., Gong, X., Functional nanocarrier for drug and gene delivery via local administration in mucosal tisúes (2018) Nanomedicine (London), 13 (1), pp. 69-88
• Telko, M.J., Hickey, A.J., Dry powder inhaler formulation (2005) Respir Care, 50 (9), pp. 1209-1227
• Abdelwahed, W., Degobert, G., Fessi H. investigation of nanocapsules stabilization by amorphous excipients during freeze-drying and storage (2006) Eur J Pharm Biopharm, 63 (2), pp. 87-94
• Igarashi, M., Ishizaki, Y., Takahashi, Y., New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development (2018) J Antibiot, 71 (1), pp. 15-25

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------